Search clinical trials for: Temsirolimus

Total 229 results

Sheba Medical Center
Stanley Medical Research Institute

Unknown

Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia

Schizophrenia | Schizoaffective Disorder

Israel
St. Joseph's Healthcare Hamilton
Pfizer; McMaster University

Completed

Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma

Renal Cell Carcinoma

Canada
AVEO Pharmaceuticals, Inc.

Completed

A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Children's Hospital Medical Center, Cincinnati

Withdrawn

Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

United States
Dana-Farber Cancer Institute
Wyeth is now a wholly owned subsidiary of Pfizer; Millennium Pharmaceuticals...

Completed

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Mathias Witzens-Harig
Charite University, Berlin, Germany; Ludwig-Maximilians - University of Munich and other collaborators

Unknown

STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma (STORM)

Diffuse Large B-Cell Lymphoma

Germany
Georgetown University
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer

Advanced Solid Tumors

United States
Goethe University

Completed

Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia (TOR-AML)

Acute Myeloblastic Leukemia

Germany
Wyeth is now a wholly owned subsidiary of Pfizer
Pfizer

Completed

Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms

Breast Neoplasms
Loyola University
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Prostate Cancer

Prostate Cancer

United States
M.D. Anderson Cancer Center

Completed

Study of Temsirolimus, Topotecan, and Bortezomib

Advanced Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Malignant Glioma

Brain and Central Nervous System Tumors

United States
Hellenic Cooperative Oncology Group

Terminated

Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse

Ovarian Cancer

Greece
AGO Study Group

Completed

Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma

Ovarian Diseases | Ovarian Neoplasms | Endometrial Neoplasms | Genital Diseases, Female

Germany
Technische Universität Dresden
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Temsirolimus in Myelodysplastic Syndrome (MDS) (TEMDS)

Myelodysplastic Syndrome

Germany
Radboud University Medical Center

Unknown

Temsirolimus-RCC-imaging

Renal Cell Cancer

Netherlands
MedSIR

Completed

POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus (POEM)

Carcinoma, Endometrioid | mTOR Protein

Spain
Federation Francophone de Cancerologie Digestive

Terminated

Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis

Liver Cancer

France
Pfizer

Withdrawn

A Post Marketing Surveillance As Required By Philippine Food And Drug Administration

Renal Cell Carcinoma
Pfizer

Completed

Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors

Neoplasms | Adenocarcinoma

United States, France, Russian Federation, Canada, Germany, Mexico, Poland
Institut Bergonié
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer (VESTOR)

Relapsed Bladder Cancer

France
Memorial Sloan Kettering Cancer Center
Pfizer; University of Wisconsin, Madison; Duke University; AEterna Zentaris; NATL...

Completed

Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors

Pediatric Solid Tumors

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States, Canada
University of Tennessee Cancer Institute
Wyeth is now a wholly owned subsidiary of Pfizer

Unknown

Temsirolimus as Second-line Therapy in HCC

Unresectable or Metastatic Hepatocellular Carcinoma

United States
The University of Texas Health Science Center at...
National Cancer Institute (NCI); Wyeth is now a wholly owned subsidiary of... and other collaborators

Completed

CCI-779 in Treating Patients With Advanced Solid Tumors

Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients

Prostatic Neoplasms

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck

Squamous Cell Carcinoma

United States
Emory University
Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis

Brain Neoplasms

United States
Mercator MedSystems, Inc.

Unknown

Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO) (TANGO)

Chronic Limb Ischemia

United States
Pfizer

Completed

Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma

Non-Hodgkin's Lymphoma

Korea, Republic of, Australia, Czechia, United States, Romania, Germany, France, Poland, Italy, Russian Federation, Serbia
Pfizer

Completed

Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Renal Cell Carcinoma

Japan
Oncology Specialists, S.C.
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

Prostate Cancer

United States
Radboud University Medical Center

Unknown

A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer

Ovarian Cancer | Endometrial Cancer | Advanced/Recurrent Breast Cancer

Netherlands
Puma Biotechnology, Inc.

Completed

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Breast Cancer

Spain, United Kingdom, France, United States, Denmark, Hong Kong
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Mantle Cell Lymphoma

France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Colombia, Portugal, Ukraine, Canada, Netherlands, Sweden, Korea, Republic of, Chile, Brazil, Russian Federation, Hungary, Ireland, Mexico, Czechia
M.D. Anderson Cancer Center

Terminated

Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

Advanced Cancers

United States
Pfizer

Completed

Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

Korea, Republic of, Japan, China
Charite University, Berlin, Germany
Pfizer

Unknown

Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma

Recurrent or Refractory Primary CNS Lymphoma

Germany
University of California, Davis
GlaxoSmithKline; Pfizer

Completed

Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors

Solid Tumors

United States
Mercator MedSystems, Inc.

Not yet recruiting

Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee (TANGO-3)

Peripheral Artery Disease | Critical Limb Ischemia
Pfizer

Completed

INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus

Carcinoma, Renal Cell | Lymphoma, Mantle-Cell

Spain
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Temsirolimus In Phase 0

Advanced Cancer

United States
Washington University School of Medicine

Completed

Temsirolimus and Radiation for Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Puma Biotechnology, Inc.

Completed

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

HER2-mutant Non-Small Cell Lung Cancer

United States, France
National Cancer Institute (NCI)

Withdrawn

A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

Glioma | Pinealoma | Brain Stem Neoplasms
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors

Brain and Central Nervous System Tumors | Metastatic Cancer

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse

Prostate Cancer

United States
Mercator MedSystems, Inc.

Recruiting

Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization (TAP-DANCE)

Peripheral Arterial Disease

United States
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Neoplasms | Malignant Carcinoma

United States, France

Search clinical trials for: Temsirolimus

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations